Advice
following a full submission
enzalutamide (Xtandi®) is accepted for use within NHS Scotland.
Indication under review: Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.
In one randomised, double-blind, phase III clinical study, enzalutamide significantly increased overall survival compared with placebo.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of enzalutamide. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice164KB (PDF)
Medicine details
- Medicine name:
- enzalutamide (Xtandi)
- SMC ID:
- 911/13
- Indication:
- Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 November 2013